Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 8 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Beagle dog assessed as urinary glucose excretion at 0.03 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 8 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 4 to 24 hrs relative to dapagliflozin
Antidiabetic activity in Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po administered 1 hr prior to glucose challenge measured after 1 to 4 hrs relative to dapagliflozin
Inhibition of full length human SGLT1 assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs by cell-based topcount scintillation counting analysis
Inhibition of full length human SGLT2 assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake after 1.5 hrs by cell-based topcount scintillation counting analysis